Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 1813 | 10118-90-8 |
Dose | Unit | Route |
---|---|---|
1 | mg | O |
0.20 | g | O |
0.20 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.87 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 97 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 17 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 30, 1971 | FDA | TRIAX PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exostosis | 454.22 | 15.69 | 195 | 25664 | 17667 | 63445496 |
Bone erosion | 452.45 | 15.69 | 194 | 25665 | 17523 | 63445640 |
Joint dislocation | 441.38 | 15.69 | 194 | 25665 | 18606 | 63444557 |
Foot deformity | 368.78 | 15.69 | 194 | 25665 | 27659 | 63435504 |
Polyarteritis nodosa | 332.57 | 15.69 | 63 | 25796 | 228 | 63462935 |
Lupus-like syndrome | 317.98 | 15.69 | 145 | 25714 | 15150 | 63448013 |
Joint stiffness | 307.63 | 15.69 | 199 | 25660 | 41670 | 63421493 |
Retinitis | 292.93 | 15.69 | 106 | 25753 | 6090 | 63457073 |
Osteoporosis | 277.47 | 15.69 | 211 | 25648 | 57127 | 63406036 |
Hepatic cirrhosis | 273.70 | 15.69 | 153 | 25706 | 24581 | 63438582 |
Osteoarthritis | 222.25 | 15.69 | 232 | 25627 | 95111 | 63368052 |
Drug intolerance | 217.68 | 15.69 | 423 | 25436 | 308238 | 63154925 |
Laryngitis | 198.77 | 15.69 | 109 | 25750 | 16858 | 63446305 |
Idiopathic intracranial hypertension | 188.13 | 15.69 | 63 | 25796 | 2868 | 63460295 |
Drug reaction with eosinophilia and systemic symptoms | 164.65 | 15.69 | 125 | 25734 | 33711 | 63429452 |
Arthritis | 154.14 | 15.69 | 212 | 25647 | 115709 | 63347454 |
Red blood cell sedimentation rate increased | 143.83 | 15.69 | 129 | 25730 | 43853 | 63419310 |
Adverse drug reaction | 136.05 | 15.69 | 165 | 25694 | 79549 | 63383614 |
General physical health deterioration | 129.61 | 15.69 | 266 | 25593 | 201136 | 63262027 |
Drug ineffective | 128.19 | 15.69 | 792 | 25067 | 1043973 | 62419190 |
Ear infection | 122.81 | 15.69 | 111 | 25748 | 38102 | 63425061 |
Ochronosis | 119.06 | 15.69 | 20 | 25839 | 27 | 63463136 |
C-reactive protein increased | 115.15 | 15.69 | 166 | 25693 | 94541 | 63368622 |
Drug-induced liver injury | 114.12 | 15.69 | 109 | 25750 | 40113 | 63423050 |
Skin hyperpigmentation | 113.23 | 15.69 | 53 | 25806 | 5868 | 63457295 |
Gastric disorder | 109.32 | 15.69 | 103 | 25756 | 37266 | 63425897 |
Thyroiditis | 101.09 | 15.69 | 38 | 25821 | 2428 | 63460735 |
Rheumatoid arthritis | 91.20 | 15.69 | 268 | 25591 | 253551 | 63209612 |
Drug hypersensitivity | 90.48 | 15.69 | 305 | 25554 | 310382 | 63152781 |
Mobility decreased | 89.90 | 15.69 | 170 | 25689 | 120989 | 63342174 |
Eosinophilic myocarditis | 81.03 | 15.69 | 23 | 25836 | 597 | 63462566 |
Lupus vulgaris | 77.13 | 15.69 | 41 | 25818 | 5953 | 63457210 |
Hypercholesterolaemia | 76.57 | 15.69 | 66 | 25793 | 21268 | 63441895 |
Therapeutic product effect incomplete | 73.16 | 15.69 | 159 | 25700 | 124897 | 63338266 |
Joint swelling | 69.79 | 15.69 | 291 | 25568 | 327375 | 63135788 |
Visual impairment | 68.28 | 15.69 | 123 | 25736 | 84323 | 63378840 |
Papilloedema | 68.24 | 15.69 | 33 | 25826 | 3927 | 63459236 |
Hidradenitis | 65.54 | 15.69 | 29 | 25830 | 2817 | 63460346 |
Synovitis | 63.87 | 15.69 | 194 | 25665 | 186724 | 63276439 |
Type 2 diabetes mellitus | 63.49 | 15.69 | 102 | 25757 | 63766 | 63399397 |
Asthenia | 63.38 | 15.69 | 39 | 25820 | 383565 | 63079598 |
Vasculitis necrotising | 60.93 | 15.69 | 18 | 25841 | 540 | 63462623 |
Hepatic enzyme increased | 60.00 | 15.69 | 200 | 25659 | 202128 | 63261035 |
Pigmentation disorder | 57.63 | 15.69 | 31 | 25828 | 4608 | 63458555 |
Dyspepsia | 57.56 | 15.69 | 128 | 25731 | 102068 | 63361095 |
Treatment failure | 57.47 | 15.69 | 195 | 25664 | 198848 | 63264315 |
Sleep disorder | 57.46 | 15.69 | 112 | 25747 | 81454 | 63381709 |
Scleral pigmentation | 56.66 | 15.69 | 9 | 25850 | 6 | 63463157 |
Death | 56.57 | 15.69 | 42 | 25817 | 374339 | 63088824 |
Bone hyperpigmentation | 54.54 | 15.69 | 9 | 25850 | 10 | 63463153 |
Abdominal distension | 53.94 | 15.69 | 113 | 25746 | 86502 | 63376661 |
Product use in unapproved indication | 53.06 | 15.69 | 177 | 25682 | 178903 | 63284260 |
Intracranial pressure increased | 51.51 | 15.69 | 30 | 25829 | 5197 | 63457966 |
Conjunctival pigmentation | 51.22 | 15.69 | 10 | 25849 | 44 | 63463119 |
Adverse reaction | 50.28 | 15.69 | 38 | 25821 | 10165 | 63452998 |
Anti-cyclic citrullinated peptide antibody positive | 49.83 | 15.69 | 131 | 25728 | 116081 | 63347082 |
Hypoaesthesia | 49.50 | 15.69 | 166 | 25693 | 168227 | 63294936 |
Rheumatoid factor positive | 47.84 | 15.69 | 106 | 25753 | 84300 | 63378863 |
Blood cholesterol increased | 47.67 | 15.69 | 113 | 25746 | 93919 | 63369244 |
Optic atrophy | 46.31 | 15.69 | 18 | 25841 | 1260 | 63461903 |
Onychomadesis | 45.92 | 15.69 | 29 | 25830 | 5811 | 63457352 |
Toxicity to various agents | 45.36 | 15.69 | 22 | 25837 | 247228 | 63215935 |
Pericarditis | 45.31 | 15.69 | 137 | 25722 | 131442 | 63331721 |
Product label confusion | 43.36 | 15.69 | 19 | 25840 | 1803 | 63461360 |
Eosinophilic pneumonia acute | 43.29 | 15.69 | 13 | 25846 | 413 | 63462750 |
Hypotension | 43.23 | 15.69 | 29 | 25830 | 272575 | 63190588 |
Rheumatic fever | 43.04 | 15.69 | 69 | 25790 | 43042 | 63420121 |
Decreased appetite | 41.46 | 15.69 | 207 | 25652 | 250845 | 63212318 |
Dyspnoea | 40.76 | 15.69 | 136 | 25723 | 661177 | 62801986 |
Back pain | 40.69 | 15.69 | 29 | 25830 | 264116 | 63199047 |
Onychomycosis | 40.10 | 15.69 | 30 | 25829 | 7902 | 63455261 |
Drug interaction | 39.63 | 15.69 | 22 | 25837 | 229109 | 63234054 |
Arthralgia | 38.91 | 15.69 | 378 | 25481 | 569332 | 62893831 |
Nail disorder | 36.38 | 15.69 | 35 | 25824 | 12980 | 63450183 |
Dermatitis acneiform | 34.82 | 15.69 | 23 | 25836 | 4973 | 63458190 |
Paronychia | 32.57 | 15.69 | 23 | 25836 | 5542 | 63457621 |
Musculoskeletal stiffness | 32.44 | 15.69 | 155 | 25704 | 184463 | 63278700 |
Urinary tract infection | 32.42 | 15.69 | 36 | 25823 | 264648 | 63198515 |
Fall | 32.18 | 15.69 | 70 | 25789 | 392264 | 63070899 |
Diarrhoea | 31.72 | 15.69 | 167 | 25692 | 715199 | 62747964 |
Hand deformity | 31.06 | 15.69 | 138 | 25721 | 159319 | 63303844 |
Henoch-Schonlein purpura | 30.54 | 15.69 | 13 | 25846 | 1150 | 63462013 |
Cough | 30.49 | 15.69 | 45 | 25814 | 292698 | 63170465 |
Completed suicide | 29.84 | 15.69 | 11 | 25848 | 145662 | 63317501 |
Constipation | 29.34 | 15.69 | 29 | 25830 | 224914 | 63238249 |
Barotrauma | 29.27 | 15.69 | 8 | 25851 | 180 | 63462983 |
Product dose omission issue | 28.55 | 15.69 | 32 | 25827 | 234281 | 63228882 |
Enterococcal sepsis | 28.06 | 15.69 | 13 | 25846 | 1405 | 63461758 |
Sinusitis | 27.56 | 15.69 | 31 | 25828 | 226622 | 63236541 |
Hepatic function abnormal | 27.36 | 15.69 | 52 | 25807 | 37090 | 63426073 |
Contraindicated product administered | 26.90 | 15.69 | 166 | 25693 | 217482 | 63245681 |
Arteritis | 26.55 | 15.69 | 10 | 25849 | 642 | 63462521 |
Wound | 26.48 | 15.69 | 134 | 25725 | 163129 | 63300034 |
Skin odour abnormal | 26.07 | 15.69 | 13 | 25846 | 1653 | 63461510 |
Coeliac disease | 26.00 | 15.69 | 29 | 25830 | 12768 | 63450395 |
Haemoglobin decreased | 25.10 | 15.69 | 14 | 25845 | 145471 | 63317692 |
Systemic lupus erythematosus | 24.36 | 15.69 | 157 | 25702 | 208761 | 63254402 |
Acute kidney injury | 24.15 | 15.69 | 44 | 25815 | 263371 | 63199792 |
Thyroiditis acute | 23.71 | 15.69 | 6 | 25853 | 99 | 63463064 |
Hepatitis | 23.70 | 15.69 | 51 | 25808 | 39737 | 63423426 |
Type 2 lepra reaction | 23.65 | 15.69 | 5 | 25854 | 35 | 63463128 |
Retinal pigmentation | 23.59 | 15.69 | 6 | 25853 | 101 | 63463062 |
Off label use | 23.45 | 15.69 | 395 | 25464 | 674067 | 62789096 |
Back injury | 23.34 | 15.69 | 24 | 25835 | 9636 | 63453527 |
Tooth discolouration | 22.73 | 15.69 | 10 | 25849 | 958 | 63462205 |
Anaemia | 22.70 | 15.69 | 54 | 25805 | 293376 | 63169787 |
Helicobacter infection | 22.55 | 15.69 | 86 | 25773 | 92699 | 63370464 |
Glossodynia | 22.45 | 15.69 | 137 | 25722 | 178739 | 63284424 |
Psoriatic arthropathy | 22.39 | 15.69 | 85 | 25774 | 91435 | 63371728 |
Condition aggravated | 22.27 | 15.69 | 256 | 25603 | 401961 | 63061202 |
Finger deformity | 21.97 | 15.69 | 21 | 25838 | 7724 | 63455439 |
Atrial fibrillation | 21.95 | 15.69 | 10 | 25849 | 116626 | 63346537 |
Abdominal pain | 21.92 | 15.69 | 55 | 25804 | 293401 | 63169762 |
Therapeutic product effect decreased | 21.80 | 15.69 | 144 | 25715 | 193043 | 63270120 |
Fibromyalgia | 21.61 | 15.69 | 77 | 25782 | 80343 | 63382820 |
Pemphigus | 21.37 | 15.69 | 138 | 25721 | 183588 | 63279575 |
Grip strength decreased | 21.33 | 15.69 | 35 | 25824 | 22252 | 63440911 |
Peripheral swelling | 21.32 | 15.69 | 48 | 25811 | 265894 | 63197269 |
Infection | 21.31 | 15.69 | 163 | 25696 | 229010 | 63234153 |
Hyperthyroidism | 21.23 | 15.69 | 28 | 25831 | 14645 | 63448518 |
Oedema peripheral | 21.22 | 15.69 | 141 | 25718 | 189370 | 63273793 |
Cerebrovascular accident | 20.74 | 15.69 | 9 | 25850 | 108015 | 63355148 |
Monocytosis | 20.66 | 15.69 | 8 | 25851 | 554 | 63462609 |
Weight decreased | 20.57 | 15.69 | 52 | 25807 | 276746 | 63186417 |
Anti-cyclic citrullinated peptide antibody | 20.46 | 15.69 | 19 | 25840 | 6739 | 63456424 |
Post inflammatory pigmentation change | 20.38 | 15.69 | 7 | 25852 | 344 | 63462819 |
Neutropenia | 20.13 | 15.69 | 25 | 25834 | 174980 | 63288183 |
Pustule | 20.12 | 15.69 | 11 | 25848 | 1688 | 63461475 |
Infusion related reaction | 19.77 | 15.69 | 169 | 25690 | 245352 | 63217811 |
Weight increased | 19.37 | 15.69 | 49 | 25810 | 260743 | 63202420 |
Tuberculin test positive | 19.37 | 15.69 | 14 | 25845 | 3497 | 63459666 |
Injection site erythema | 19.33 | 15.69 | 5 | 25854 | 83169 | 63379994 |
Somnolence | 19.05 | 15.69 | 27 | 25832 | 178658 | 63284505 |
Hyponatraemia | 18.96 | 15.69 | 11 | 25848 | 111889 | 63351274 |
Injury | 18.72 | 15.69 | 69 | 25790 | 73178 | 63389985 |
Flushing | 18.46 | 15.69 | 4 | 25855 | 75083 | 63388080 |
Adverse event | 18.42 | 15.69 | 65 | 25794 | 67494 | 63395669 |
Dehiscence | 18.40 | 15.69 | 5 | 25854 | 110 | 63463053 |
Influenza | 17.98 | 15.69 | 11 | 25848 | 108711 | 63354452 |
COVID-19 | 17.95 | 15.69 | 12 | 25847 | 113091 | 63350072 |
Bradycardia | 17.80 | 15.69 | 4 | 25855 | 73223 | 63389940 |
Antinuclear antibody positive | 17.77 | 15.69 | 19 | 25840 | 7980 | 63455183 |
Pigment nephropathy | 17.74 | 15.69 | 4 | 25855 | 39 | 63463124 |
Dehydration | 17.69 | 15.69 | 27 | 25832 | 173327 | 63289836 |
Mononeuropathy multiplex | 17.65 | 15.69 | 6 | 25853 | 286 | 63462877 |
Blood creatinine increased | 17.38 | 15.69 | 7 | 25852 | 87837 | 63375326 |
Antinuclear antibody increased | 16.87 | 15.69 | 9 | 25850 | 1316 | 63461847 |
Malaise | 16.82 | 15.69 | 250 | 25609 | 415704 | 63047459 |
Mononeuropathy | 16.68 | 15.69 | 5 | 25854 | 158 | 63463005 |
Discomfort | 16.65 | 15.69 | 121 | 25738 | 167253 | 63295910 |
Injection site pain | 16.61 | 15.69 | 17 | 25842 | 129783 | 63333380 |
Hyperhidrosis | 16.37 | 15.69 | 12 | 25847 | 107824 | 63355339 |
Cardiovascular disorder | 16.26 | 15.69 | 22 | 25837 | 11790 | 63451373 |
Overdose | 15.98 | 15.69 | 14 | 25845 | 115064 | 63348099 |
Depressed level of consciousness | 15.90 | 15.69 | 3 | 25856 | 62075 | 63401088 |
Nasopharyngitis | 15.79 | 15.69 | 52 | 25807 | 254205 | 63208958 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Apparent death | 228.41 | 20.25 | 70 | 9555 | 3574 | 34943732 |
Photosensitivity reaction | 218.51 | 20.25 | 89 | 9536 | 10505 | 34936801 |
Red blood cell sedimentation rate increased | 202.84 | 20.25 | 81 | 9544 | 9081 | 34938225 |
Terminal state | 202.44 | 20.25 | 65 | 9560 | 3869 | 34943437 |
C-reactive protein abnormal | 189.34 | 20.25 | 76 | 9549 | 8634 | 34938672 |
Interstitial lung disease | 189.28 | 20.25 | 151 | 9474 | 65131 | 34882175 |
Skin hyperpigmentation | 184.77 | 20.25 | 58 | 9567 | 3206 | 34944100 |
Pulmonary thrombosis | 183.34 | 20.25 | 71 | 9554 | 7336 | 34939970 |
Stomatitis | 181.03 | 20.25 | 124 | 9501 | 42390 | 34904916 |
Intestinal sepsis | 143.56 | 20.25 | 34 | 9591 | 637 | 34946669 |
Polyarteritis nodosa | 140.71 | 20.25 | 29 | 9596 | 275 | 34947031 |
Pigmentation disorder | 136.10 | 20.25 | 43 | 9582 | 2426 | 34944880 |
Diverticulitis | 129.23 | 20.25 | 76 | 9549 | 19928 | 34927378 |
Scleral pigmentation | 122.38 | 20.25 | 17 | 9608 | 0 | 34947306 |
Dermatitis acneiform | 120.78 | 20.25 | 50 | 9575 | 6139 | 34941167 |
Herpes zoster | 117.95 | 20.25 | 88 | 9537 | 34311 | 34912995 |
Joint arthroplasty | 114.48 | 20.25 | 30 | 9595 | 861 | 34946445 |
Contraindicated product administered | 106.63 | 20.25 | 69 | 9556 | 21412 | 34925894 |
Urticaria | 95.48 | 20.25 | 101 | 9524 | 62276 | 34885030 |
Bone hyperpigmentation | 94.45 | 20.25 | 14 | 9611 | 8 | 34947298 |
Joint swelling | 91.71 | 20.25 | 97 | 9528 | 59793 | 34887513 |
C-reactive protein increased | 88.89 | 20.25 | 91 | 9534 | 54007 | 34893299 |
Arthropathy | 88.13 | 20.25 | 67 | 9558 | 26840 | 34920466 |
Thrombosis | 83.11 | 20.25 | 85 | 9540 | 50373 | 34896933 |
Paronychia | 81.96 | 20.25 | 32 | 9593 | 3373 | 34943933 |
Ochronosis | 79.18 | 20.25 | 11 | 9614 | 0 | 34947306 |
Feeling abnormal | 78.85 | 20.25 | 92 | 9533 | 63143 | 34884163 |
Knee arthroplasty | 75.07 | 20.25 | 38 | 9587 | 7406 | 34939900 |
Drug intolerance | 73.15 | 20.25 | 86 | 9539 | 59484 | 34887822 |
Thyroiditis | 70.58 | 20.25 | 26 | 9599 | 2336 | 34944970 |
Deep vein thrombosis | 70.04 | 20.25 | 88 | 9537 | 65160 | 34882146 |
Pulmonary embolism | 66.21 | 20.25 | 101 | 9524 | 89645 | 34857661 |
Drug hypersensitivity | 65.68 | 20.25 | 95 | 9530 | 80434 | 34866872 |
Stent placement | 63.42 | 20.25 | 30 | 9595 | 5048 | 34942258 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 58.84 | 20.25 | 18 | 9607 | 911 | 34946395 |
Drug reaction with eosinophilia and systemic symptoms | 53.21 | 20.25 | 55 | 9570 | 32957 | 34914349 |
Intentional product use issue | 50.84 | 20.25 | 72 | 9553 | 59744 | 34887562 |
Scleral discolouration | 49.36 | 20.25 | 12 | 9613 | 252 | 34947054 |
Haemoglobin decreased | 44.70 | 20.25 | 101 | 9524 | 120671 | 34826635 |
Drug ineffective | 42.88 | 20.25 | 242 | 9383 | 456509 | 34490797 |
Renal failure | 42.67 | 20.25 | 104 | 9521 | 130453 | 34816853 |
Thyroiditis acute | 42.04 | 20.25 | 9 | 9616 | 104 | 34947202 |
Retinal pigmentation | 40.13 | 20.25 | 6 | 9619 | 4 | 34947302 |
Autoimmune thyroiditis | 39.09 | 20.25 | 14 | 9611 | 1160 | 34946146 |
Glomerulonephritis rapidly progressive | 38.51 | 20.25 | 12 | 9613 | 646 | 34946660 |
Sepsis | 36.83 | 20.25 | 115 | 9510 | 166446 | 34780860 |
Skin discolouration | 36.73 | 20.25 | 34 | 9591 | 17811 | 34929495 |
Cardiac valve discolouration | 35.99 | 20.25 | 5 | 9620 | 0 | 34947306 |
Serum sickness-like reaction | 33.91 | 20.25 | 8 | 9617 | 147 | 34947159 |
Death | 32.70 | 20.25 | 37 | 9588 | 398012 | 34549294 |
Vasculitis | 32.35 | 20.25 | 26 | 9599 | 11270 | 34936036 |
Pemphigoid | 31.52 | 20.25 | 23 | 9602 | 8643 | 34938663 |
Acute febrile neutrophilic dermatosis | 30.49 | 20.25 | 12 | 9613 | 1291 | 34946015 |
Skin depigmentation | 29.98 | 20.25 | 9 | 9616 | 427 | 34946879 |
Red blood cell sedimentation rate abnormal | 29.55 | 20.25 | 16 | 9609 | 3573 | 34943733 |
Tissue discolouration | 28.79 | 20.25 | 4 | 9621 | 0 | 34947306 |
Gingival hyperpigmentation | 28.79 | 20.25 | 4 | 9621 | 0 | 34947306 |
Hepatic function abnormal | 28.61 | 20.25 | 47 | 9578 | 44316 | 34902990 |
Eosinophilic pneumonia acute | 28.02 | 20.25 | 9 | 9616 | 535 | 34946771 |
Hyperthyroidism | 27.49 | 20.25 | 23 | 9602 | 10543 | 34936763 |
Peripheral sensory neuropathy | 27.02 | 20.25 | 19 | 9606 | 6741 | 34940565 |
Nail discolouration | 26.10 | 20.25 | 10 | 9615 | 1001 | 34946305 |
IIIrd nerve paralysis | 24.30 | 20.25 | 8 | 9617 | 514 | 34946792 |
Melanocytic naevus | 23.73 | 20.25 | 12 | 9613 | 2332 | 34944974 |
Myocardial infarction | 23.48 | 20.25 | 80 | 9545 | 121005 | 34826301 |
Testicular infarction | 23.42 | 20.25 | 5 | 9620 | 57 | 34947249 |
Pharyngeal inflammation | 23.36 | 20.25 | 7 | 9618 | 330 | 34946976 |
Jarisch-Herxheimer reaction | 23.33 | 20.25 | 8 | 9617 | 583 | 34946723 |
Dyspnoea | 23.07 | 20.25 | 43 | 9582 | 376739 | 34570567 |
Protein total abnormal | 23.04 | 20.25 | 7 | 9618 | 346 | 34946960 |
Post procedural infection | 22.61 | 20.25 | 15 | 9610 | 4841 | 34942465 |
Testicular pain | 21.65 | 20.25 | 12 | 9613 | 2806 | 34944500 |
Joint deposit | 21.59 | 20.25 | 3 | 9622 | 0 | 34947306 |
Hypotension | 21.15 | 20.25 | 18 | 9607 | 221631 | 34725675 |
Tooth injury | 21.04 | 20.25 | 9 | 9616 | 1196 | 34946110 |
Breast inflammation | 20.36 | 20.25 | 4 | 9621 | 29 | 34947277 |
Thyroid disorder | 20.29 | 20.25 | 12 | 9613 | 3170 | 34944136 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Polyarteritis nodosa | 415.13 | 14.80 | 83 | 30088 | 462 | 79713755 |
Exostosis | 296.01 | 14.80 | 139 | 30032 | 16719 | 79697498 |
Joint dislocation | 295.38 | 14.80 | 139 | 30032 | 16800 | 79697417 |
Lupus-like syndrome | 292.89 | 14.80 | 130 | 30041 | 13727 | 79700490 |
Bone erosion | 288.46 | 14.80 | 139 | 30032 | 17708 | 79696509 |
Skin hyperpigmentation | 287.19 | 14.80 | 107 | 30064 | 7196 | 79707021 |
Red blood cell sedimentation rate increased | 263.27 | 14.80 | 182 | 29989 | 45760 | 79668457 |
Retinitis | 252.73 | 14.80 | 91 | 30080 | 5552 | 79708665 |
Foot deformity | 251.94 | 14.80 | 140 | 30031 | 23934 | 79690283 |
Drug intolerance | 224.79 | 14.80 | 377 | 29794 | 263742 | 79450475 |
Joint stiffness | 206.72 | 14.80 | 150 | 30021 | 40680 | 79673537 |
Drug reaction with eosinophilia and systemic symptoms | 199.11 | 14.80 | 177 | 29994 | 64067 | 79650150 |
Hepatic cirrhosis | 194.60 | 14.80 | 136 | 30035 | 34770 | 79679447 |
Apparent death | 185.99 | 14.80 | 61 | 30110 | 2804 | 79711413 |
Pigmentation disorder | 180.32 | 14.80 | 71 | 30100 | 5547 | 79708670 |
Ochronosis | 176.59 | 14.80 | 29 | 30142 | 35 | 79714182 |
Osteoporosis | 175.50 | 14.80 | 153 | 30018 | 53959 | 79660258 |
Laryngitis | 169.78 | 14.80 | 94 | 30077 | 15945 | 79698272 |
Scleral pigmentation | 159.78 | 14.80 | 24 | 30147 | 6 | 79714211 |
Thyroiditis | 157.70 | 14.80 | 61 | 30110 | 4544 | 79709673 |
Terminal state | 147.19 | 14.80 | 59 | 30112 | 4830 | 79709387 |
C-reactive protein increased | 147.11 | 14.80 | 211 | 29960 | 128816 | 79585401 |
Drug ineffective | 142.23 | 14.80 | 791 | 29380 | 1080122 | 78634095 |
Joint swelling | 139.42 | 14.80 | 325 | 29846 | 288321 | 79425896 |
Drug hypersensitivity | 138.35 | 14.80 | 331 | 29840 | 298585 | 79415632 |
Dermatitis acneiform | 138.15 | 14.80 | 70 | 30101 | 9923 | 79704294 |
Bone hyperpigmentation | 135.15 | 14.80 | 22 | 30149 | 24 | 79714193 |
Photosensitivity reaction | 124.04 | 14.80 | 85 | 30086 | 21042 | 79693175 |
Gastric disorder | 121.66 | 14.80 | 106 | 30065 | 37327 | 79676890 |
Idiopathic intracranial hypertension | 118.64 | 14.80 | 45 | 30126 | 3177 | 79711040 |
Osteoarthritis | 117.90 | 14.80 | 155 | 30016 | 87154 | 79627063 |
Contraindicated product administered | 114.45 | 14.80 | 210 | 29961 | 157328 | 79556889 |
Pulmonary thrombosis | 109.10 | 14.80 | 64 | 30107 | 12107 | 79702110 |
Ear infection | 108.88 | 14.80 | 96 | 30075 | 34336 | 79679881 |
Paronychia | 108.83 | 14.80 | 55 | 30116 | 7753 | 79706464 |
Adverse drug reaction | 104.10 | 14.80 | 127 | 30044 | 66265 | 79647952 |
Drug-induced liver injury | 99.68 | 14.80 | 124 | 30047 | 65993 | 79648224 |
Eosinophilic pneumonia acute | 98.82 | 14.80 | 30 | 30141 | 1068 | 79713149 |
Interstitial lung disease | 98.57 | 14.80 | 163 | 30008 | 112437 | 79601780 |
Synovitis | 97.19 | 14.80 | 191 | 29980 | 150543 | 79563674 |
Intestinal sepsis | 95.85 | 14.80 | 28 | 30143 | 871 | 79713346 |
Stomatitis | 94.67 | 14.80 | 186 | 29985 | 146571 | 79567646 |
Arthritis | 88.31 | 14.80 | 157 | 30014 | 114723 | 79599494 |
C-reactive protein abnormal | 88.24 | 14.80 | 100 | 30071 | 48267 | 79665950 |
Treatment failure | 87.74 | 14.80 | 197 | 29974 | 170289 | 79543928 |
Rheumatoid arthritis | 85.91 | 14.80 | 221 | 29950 | 208249 | 79505968 |
Joint arthroplasty | 82.25 | 14.80 | 33 | 30138 | 2707 | 79711510 |
Toxicity to various agents | 77.99 | 14.80 | 31 | 30140 | 421509 | 79292708 |
Anti-cyclic citrullinated peptide antibody positive | 77.69 | 14.80 | 124 | 30047 | 83019 | 79631198 |
Hypotension | 77.27 | 14.80 | 35 | 30136 | 440282 | 79273935 |
General physical health deterioration | 72.55 | 14.80 | 249 | 29922 | 274989 | 79439228 |
Death | 72.15 | 14.80 | 65 | 30106 | 566449 | 79147768 |
Systemic lupus erythematosus | 71.49 | 14.80 | 148 | 30023 | 121001 | 79593216 |
Pemphigus | 70.07 | 14.80 | 131 | 30040 | 99451 | 79614766 |
Rheumatoid factor positive | 69.80 | 14.80 | 99 | 30072 | 59740 | 79654477 |
Eosinophilic myocarditis | 67.33 | 14.80 | 23 | 30148 | 1199 | 79713018 |
Rheumatic fever | 66.18 | 14.80 | 67 | 30104 | 28458 | 79685759 |
Vasculitis necrotising | 65.94 | 14.80 | 23 | 30148 | 1277 | 79712940 |
Drug interaction | 65.39 | 14.80 | 38 | 30133 | 415145 | 79299072 |
Hand deformity | 64.92 | 14.80 | 130 | 30041 | 103789 | 79610428 |
Mobility decreased | 64.88 | 14.80 | 143 | 30028 | 122032 | 79592185 |
Pericarditis | 64.64 | 14.80 | 130 | 30041 | 104106 | 79610111 |
Thyroiditis acute | 64.35 | 14.80 | 15 | 30156 | 186 | 79714031 |
Glossodynia | 64.23 | 14.80 | 129 | 30042 | 103208 | 79611009 |
Lupus vulgaris | 63.09 | 14.80 | 29 | 30142 | 3317 | 79710900 |
Hidradenitis | 62.51 | 14.80 | 28 | 30143 | 3016 | 79711201 |
Dyspnoea | 61.49 | 14.80 | 147 | 30024 | 856878 | 78857339 |
Completed suicide | 60.80 | 14.80 | 10 | 30161 | 245757 | 79468460 |
Adverse reaction | 60.72 | 14.80 | 40 | 30131 | 9274 | 79704943 |
Asthenia | 59.04 | 14.80 | 64 | 30107 | 511625 | 79202592 |
Sleep disorder | 56.92 | 14.80 | 110 | 30061 | 85567 | 79628650 |
Dyspepsia | 56.33 | 14.80 | 126 | 30045 | 108561 | 79605656 |
Wound | 56.14 | 14.80 | 131 | 30040 | 116048 | 79598169 |
Onychomadesis | 53.49 | 14.80 | 30 | 30141 | 5212 | 79709005 |
Hepatic enzyme increased | 53.23 | 14.80 | 171 | 30000 | 182439 | 79531778 |
Scleral discolouration | 51.98 | 14.80 | 16 | 30155 | 597 | 79713620 |
Conjunctival pigmentation | 51.96 | 14.80 | 10 | 30161 | 44 | 79714173 |
Visual impairment | 51.37 | 14.80 | 110 | 30061 | 92021 | 79622196 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 51.18 | 14.80 | 26 | 30145 | 3703 | 79710514 |
Product label confusion | 46.80 | 14.80 | 19 | 30152 | 1607 | 79712610 |
Hepatic function abnormal | 46.30 | 14.80 | 92 | 30079 | 73015 | 79641202 |
Hyperthyroidism | 44.08 | 14.80 | 48 | 30123 | 22161 | 79692056 |
Onychomycosis | 43.26 | 14.80 | 31 | 30140 | 8230 | 79705987 |
Serum sickness-like reaction | 43.16 | 14.80 | 14 | 30157 | 621 | 79713596 |
Therapeutic product effect incomplete | 42.50 | 14.80 | 134 | 30037 | 141511 | 79572706 |
Drug abuse | 41.64 | 14.80 | 6 | 30165 | 162685 | 79551532 |
Abdominal distension | 41.37 | 14.80 | 119 | 30052 | 119531 | 79594686 |
Diverticulitis | 40.83 | 14.80 | 67 | 30104 | 45869 | 79668348 |
Musculoskeletal stiffness | 39.82 | 14.80 | 151 | 30020 | 174857 | 79539360 |
Back pain | 38.53 | 14.80 | 35 | 30136 | 304145 | 79410072 |
Therapeutic product effect decreased | 37.79 | 14.80 | 142 | 30029 | 163721 | 79550496 |
Knee arthroplasty | 36.99 | 14.80 | 62 | 30109 | 43186 | 79671031 |
Cough | 35.86 | 14.80 | 52 | 30119 | 366737 | 79347480 |
Product dose omission issue | 35.72 | 14.80 | 25 | 30146 | 247512 | 79466705 |
Gingival hyperpigmentation | 35.40 | 14.80 | 6 | 30165 | 10 | 79714207 |
Type 2 diabetes mellitus | 35.10 | 14.80 | 71 | 30100 | 57051 | 79657166 |
Retinal pigmentation | 34.56 | 14.80 | 8 | 30163 | 96 | 79714121 |
Cardiac valve discolouration | 34.40 | 14.80 | 5 | 30166 | 0 | 79714217 |
Acute febrile neutrophilic dermatosis | 33.75 | 14.80 | 20 | 30151 | 3852 | 79710365 |
Blood cholesterol increased | 33.65 | 14.80 | 88 | 30083 | 83632 | 79630585 |
Urticaria | 33.59 | 14.80 | 149 | 30022 | 185052 | 79529165 |
Nail disorder | 33.43 | 14.80 | 31 | 30140 | 11821 | 79702396 |
Papilloedema | 31.75 | 14.80 | 23 | 30148 | 6210 | 79708007 |
Acute kidney injury | 31.20 | 14.80 | 97 | 30074 | 519307 | 79194910 |
Product use in unapproved indication | 31.05 | 14.80 | 181 | 29990 | 250178 | 79464039 |
Mononeuropathy multiplex | 30.90 | 14.80 | 10 | 30161 | 440 | 79713777 |
Stent placement | 30.82 | 14.80 | 23 | 30148 | 6497 | 79707720 |
Fall | 30.04 | 14.80 | 90 | 30081 | 487539 | 79226678 |
Discomfort | 29.90 | 14.80 | 110 | 30061 | 125507 | 79588710 |
Liver injury | 29.73 | 14.80 | 66 | 30105 | 56548 | 79657669 |
Barotrauma | 29.36 | 14.80 | 8 | 30163 | 192 | 79714025 |
Infection | 28.85 | 14.80 | 173 | 29998 | 241539 | 79472678 |
Coeliac disease | 28.80 | 14.80 | 28 | 30143 | 11323 | 79702894 |
Arthropathy | 28.79 | 14.80 | 138 | 30033 | 176973 | 79537244 |
Overdose | 28.76 | 14.80 | 17 | 30154 | 184189 | 79530028 |
Mononeuropathy | 28.75 | 14.80 | 8 | 30163 | 208 | 79714009 |
Decreased appetite | 28.35 | 14.80 | 224 | 29947 | 342194 | 79372023 |
Psoriatic arthropathy | 28.34 | 14.80 | 79 | 30092 | 77920 | 79636297 |
Neutropenia | 27.90 | 14.80 | 41 | 30130 | 287669 | 79426548 |
Coma | 27.48 | 14.80 | 3 | 30168 | 100646 | 79613571 |
Somnolence | 27.38 | 14.80 | 30 | 30141 | 238951 | 79475266 |
Atrial fibrillation | 27.22 | 14.80 | 21 | 30150 | 197865 | 79516352 |
Cardiac failure congestive | 27.07 | 14.80 | 10 | 30161 | 142392 | 79571825 |
Vasculitis | 27.03 | 14.80 | 40 | 30131 | 25062 | 79689155 |
Thrombosis | 26.54 | 14.80 | 81 | 30090 | 84019 | 79630198 |
Weight increased | 26.44 | 14.80 | 40 | 30131 | 277346 | 79436871 |
Cerebrovascular accident | 26.18 | 14.80 | 13 | 30158 | 155279 | 79558938 |
Intracranial pressure increased | 25.89 | 14.80 | 23 | 30148 | 8299 | 79705918 |
Urinary tract infection | 25.76 | 14.80 | 40 | 30131 | 274472 | 79439745 |
Deep vein thrombosis | 25.59 | 14.80 | 102 | 30069 | 120817 | 79593400 |
Type 1 diabetes mellitus | 25.35 | 14.80 | 21 | 30150 | 6898 | 79707319 |
Tissue discolouration | 25.28 | 14.80 | 4 | 30167 | 3 | 79714214 |
Herpes zoster | 25.15 | 14.80 | 85 | 30086 | 92998 | 79621219 |
Hypercholesterolaemia | 25.15 | 14.80 | 37 | 30134 | 23058 | 79691159 |
Tooth discolouration | 24.90 | 14.80 | 11 | 30160 | 1146 | 79713071 |
Alopecia | 24.74 | 14.80 | 161 | 30010 | 231194 | 79483023 |
Hypoaesthesia | 24.43 | 14.80 | 133 | 30038 | 179219 | 79534998 |
Arthralgia | 24.22 | 14.80 | 326 | 29845 | 571477 | 79142740 |
Glomerulonephritis rapidly progressive | 24.11 | 14.80 | 12 | 30159 | 1636 | 79712581 |
Anti-cyclic citrullinated peptide antibody | 24.06 | 14.80 | 19 | 30152 | 5833 | 79708384 |
Finger deformity | 23.94 | 14.80 | 21 | 30150 | 7453 | 79706764 |
Swollen joint count increased | 23.92 | 14.80 | 36 | 30135 | 22891 | 79691326 |
Type 2 lepra reaction | 23.86 | 14.80 | 7 | 30164 | 221 | 79713996 |
Arteritis | 23.86 | 14.80 | 10 | 30161 | 917 | 79713300 |
Peripheral sensory neuropathy | 23.85 | 14.80 | 27 | 30144 | 13006 | 79701211 |
Jarisch-Herxheimer reaction | 23.55 | 14.80 | 10 | 30161 | 947 | 79713270 |
Pemphigoid | 23.51 | 14.80 | 29 | 30142 | 15286 | 79698931 |
Hyponatraemia | 23.06 | 14.80 | 20 | 30151 | 177828 | 79536389 |
Intentional product use issue | 22.91 | 14.80 | 116 | 30055 | 151996 | 79562221 |
Off label use | 22.85 | 14.80 | 475 | 29696 | 906740 | 78807477 |
Autoimmune thyroiditis | 22.43 | 14.80 | 16 | 30155 | 4217 | 79710000 |
Grip strength decreased | 22.34 | 14.80 | 34 | 30137 | 21835 | 79692382 |
Confusional state | 22.33 | 14.80 | 55 | 30116 | 317942 | 79396275 |
Vomiting | 22.29 | 14.80 | 154 | 30017 | 665674 | 79048543 |
Tremor | 22.21 | 14.80 | 19 | 30152 | 170064 | 79544153 |
Testicular infarction | 21.83 | 14.80 | 5 | 30166 | 57 | 79714160 |
Skin discolouration | 21.72 | 14.80 | 48 | 30123 | 40986 | 79673231 |
Testicular pain | 21.56 | 14.80 | 12 | 30159 | 2053 | 79712164 |
Back injury | 21.33 | 14.80 | 23 | 30148 | 10500 | 79703717 |
Abdominal discomfort | 21.28 | 14.80 | 165 | 30006 | 250562 | 79463655 |
Skin odour abnormal | 21.16 | 14.80 | 12 | 30159 | 2129 | 79712088 |
Antinuclear antibody positive | 21.03 | 14.80 | 20 | 30151 | 7870 | 79706347 |
Enterococcal sepsis | 20.98 | 14.80 | 13 | 30158 | 2713 | 79711504 |
Hepatitis | 20.79 | 14.80 | 57 | 30114 | 55670 | 79658547 |
Agitation | 20.71 | 14.80 | 6 | 30165 | 99709 | 79614508 |
Joint deposit | 20.64 | 14.80 | 3 | 30168 | 0 | 79714217 |
Abdominal pain | 20.48 | 14.80 | 77 | 30094 | 389492 | 79324725 |
Bradycardia | 20.47 | 14.80 | 13 | 30158 | 135544 | 79578673 |
Cardiac arrest | 20.38 | 14.80 | 21 | 30150 | 172075 | 79542142 |
Hypersensitivity | 20.31 | 14.80 | 169 | 30002 | 262070 | 79452147 |
Rash | 20.23 | 14.80 | 319 | 29852 | 578039 | 79136178 |
Sinusitis | 19.79 | 14.80 | 27 | 30144 | 195474 | 79518743 |
Monocytosis | 19.70 | 14.80 | 9 | 30162 | 1015 | 79713202 |
Hyperhidrosis | 19.68 | 14.80 | 17 | 30154 | 151475 | 79562742 |
Pharyngeal inflammation | 19.65 | 14.80 | 9 | 30162 | 1021 | 79713196 |
Product use issue | 19.45 | 14.80 | 141 | 30030 | 209681 | 79504536 |
Gingival discolouration | 19.21 | 14.80 | 6 | 30165 | 235 | 79713982 |
COVID-19 | 18.94 | 14.80 | 19 | 30152 | 157655 | 79556562 |
Injection site pain | 18.86 | 14.80 | 13 | 30158 | 129825 | 79584392 |
Blood pressure increased | 18.70 | 14.80 | 32 | 30139 | 211328 | 79502889 |
Pulmonary embolism | 18.67 | 14.80 | 120 | 30051 | 171534 | 79542683 |
Henoch-Schonlein purpura | 18.55 | 14.80 | 12 | 30159 | 2698 | 79711519 |
Cardio-respiratory arrest | 18.41 | 14.80 | 9 | 30162 | 108501 | 79605716 |
Drug ineffective for unapproved indication | 17.73 | 14.80 | 51 | 30120 | 51187 | 79663030 |
Constipation | 17.58 | 14.80 | 52 | 30119 | 282998 | 79431219 |
Inflammation | 17.41 | 14.80 | 76 | 30095 | 93677 | 79620540 |
Chills | 17.39 | 14.80 | 21 | 30150 | 160213 | 79554004 |
Nail pigmentation | 17.32 | 14.80 | 6 | 30165 | 326 | 79713891 |
Protein total abnormal | 17.29 | 14.80 | 7 | 30164 | 588 | 79713629 |
Pigment nephropathy | 17.20 | 14.80 | 4 | 30167 | 49 | 79714168 |
Injury | 16.89 | 14.80 | 66 | 30105 | 77430 | 79636787 |
Salt craving | 16.58 | 14.80 | 4 | 30167 | 58 | 79714159 |
Death neonatal | 16.43 | 14.80 | 7 | 30164 | 668 | 79713549 |
Anaemia | 16.35 | 14.80 | 100 | 30071 | 444915 | 79269302 |
Influenza | 16.29 | 14.80 | 15 | 30156 | 129591 | 79584626 |
Stress | 16.15 | 14.80 | 5 | 30166 | 79607 | 79634610 |
Blood glucose increased | 16.06 | 14.80 | 12 | 30159 | 114963 | 79599254 |
Chest pain | 16.02 | 14.80 | 54 | 30117 | 282250 | 79431967 |
International normalised ratio increased | 16.01 | 14.80 | 6 | 30165 | 84715 | 79629502 |
Skin depigmentation | 16.00 | 14.80 | 8 | 30163 | 1102 | 79713115 |
Duodenal ulcer perforation | 15.76 | 14.80 | 58 | 30113 | 66153 | 79648064 |
Peripheral swelling | 15.70 | 14.80 | 51 | 30120 | 269566 | 79444651 |
Varicocele | 15.62 | 14.80 | 3 | 30168 | 13 | 79714204 |
IIIrd nerve paralysis | 15.45 | 14.80 | 8 | 30163 | 1185 | 79713032 |
Loss of consciousness | 15.25 | 14.80 | 25 | 30146 | 167918 | 79546299 |
Wound secretion | 15.21 | 14.80 | 15 | 30156 | 6173 | 79708044 |
Lactic acidosis | 15.05 | 14.80 | 4 | 30167 | 70355 | 79643862 |
Infusion related reaction | 15.04 | 14.80 | 143 | 30028 | 230094 | 79484123 |
None
Source | Code | Description |
---|---|---|
ATC | A01AB23 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment |
ATC | D10AF07 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne |
ATC | J01AA08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines |
FDA CS | M0021223 | Tetracyclines |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
FDA EPC | N0000175882 | Tetracycline-class Drug |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
CHEBI has role | CHEBI:176497 | geroprotectors |
FDA PE | N0000193995 | Decreased Prothrombin Activity |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Trachoma | indication | 2576002 | DOID:11265 |
Listeriosis | indication | 4241002 | DOID:11573 |
Actinomycotic infection | indication | 11817007 | DOID:8478 |
Gonorrhea | indication | 15628003 | DOID:7551 |
Tularemia | indication | 19265001 | |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Gingivostomatitis | indication | 20607006 | |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Granuloma inguinale | indication | 28867007 | DOID:9113 |
Acute gonococcal urethritis | indication | 29864006 | |
Bronchitis | indication | 32398004 | DOID:6132 |
Sinusitis | indication | 36971009 | |
Periodontitis | indication | 41565005 | DOID:824 |
Gonorrhea of rectum | indication | 42746002 | |
Plague | indication | 58750007 | DOID:3482 |
Cholera | indication | 63650001 | DOID:1498 |
Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
Urinary tract infectious disease | indication | 68566005 | |
Yaws | indication | 70647001 | DOID:10371 |
Gonorrhea of pharynx | indication | 74372003 | |
Rickettsialpox | indication | 75096007 | DOID:11103 |
Ornithosis | indication | 75116005 | DOID:11262 |
Brucellosis | indication | 75702008 | DOID:11077 |
Syphilis | indication | 76272004 | |
Acne vulgaris | indication | 88616000 | |
Infection by Campylobacter fetus | indication | 111835002 | |
Meningococcus carrier | indication | 170486006 | |
Rocky Mountain spotted fever | indication | 186772009 | |
Q fever | indication | 186788009 | DOID:11100 |
Lymphogranuloma venereum | indication | 186946009 | DOID:13819 |
Pneumonia | indication | 233604007 | DOID:552 |
Inclusion conjunctivitis | indication | 266109000 | |
Bartonellosis | indication | 266123003 | DOID:11102 |
Chancroid | indication | 266143009 | DOID:13778 |
Infective otitis media | indication | 312218008 | |
Fusospirochetal pharyngitis | indication | 399095008 | |
Pharyngitis | indication | 405737000 | DOID:2275 |
Anthrax | indication | 409498004 | DOID:7427 |
Relapsing fever | indication | 420079008 | DOID:13034 |
Chlamydia trachomatis infection of genital structure | indication | 428015005 | |
Rectal Chlamydia Trachomatis Infection | indication | ||
Ureaplasma Urealyticum Infections | indication | ||
Typhus Infections | indication | ||
Nocardiosis | off-label use | 29227009 | DOID:2312 |
Enterocolitis | off-label use | 43752006 | |
Pneumonia due to Mycoplasma pneumoniae | off-label use | 46970008 | |
Rheumatoid arthritis | off-label use | 69896004 | DOID:7148 |
Leprosy | off-label use | 81004002 | DOID:1024 |
Cholangitis | off-label use | 82403002 | DOID:9446 |
Mycobacteriosis | off-label use | 88415009 | |
Chlamydial infection | off-label use | 105629000 | |
Infectious disease of abdomen | off-label use | 128070006 | |
Ocular rosacea | off-label use | 200933006 | |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Pregnancy, function | contraindication | 289908002 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Azotemia | contraindication | 445009001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.13 | acidic |
pKa2 | 8.85 | acidic |
pKa3 | 11.14 | acidic |
pKa4 | 11.96 | acidic |
pKa5 | 13.08 | acidic |
pKa6 | 9.55 | Basic |
pKa7 | 4.82 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 105MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 105MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 105MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 105MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8722650 | June 24, 2025 | TREATMENT OF ACNE |
EQ 115MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 115MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 115MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 55MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 55MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 55MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 55MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8722650 | June 24, 2025 | TREATMENT OF ACNE |
EQ 65MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 65MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 65MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 80MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 80MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 80MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 80MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 8722650 | June 24, 2025 | TREATMENT OF ACNE |
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 135MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 135MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 135MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 45MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 45MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 45MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 90MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7790705 | June 24, 2025 | TREATMENT OF ACNE |
EQ 90MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8252776 | June 24, 2025 | TREATMENT OF ACNE |
EQ 90MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8268804 | June 24, 2025 | TREATMENT OF ACNE |
EQ 105MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 115MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 55MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 65MG BASE | SOLODYN | BAUSCH | N050808 | July 23, 2009 | RX | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 80MG BASE | SOLODYN | BAUSCH | N050808 | Aug. 27, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 135MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 45MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 90MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7919483 | March 7, 2027 | TREATMENT OF ACNE |
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLODYN | BAUSCH | N050808 | May 8, 2006 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7541347 | April 2, 2027 | TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS |
EQ 135MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7541347 | April 2, 2027 | TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS |
EQ 45MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7541347 | April 2, 2027 | TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS |
EQ 90MG BASE | XIMINO | JOURNEY | N201922 | July 11, 2012 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 7541347 | April 2, 2027 | TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10086080 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10137200 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10213512 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10517882 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10821187 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 8865139 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 8992896 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 9675700 | Oct. 1, 2030 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 1.5% BASE | ZILXI | JOURNEY | N213690 | May 28, 2020 | RX | AEROSOL, FOAM | TOPICAL | 10213512 | Oct. 1, 2030 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
EQ 1.5% BASE | ZILXI | JOURNEY | N213690 | May 28, 2020 | RX | AEROSOL, FOAM | TOPICAL | 10322186 | Oct. 1, 2030 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
EQ 1.5% BASE | ZILXI | JOURNEY | N213690 | May 28, 2020 | RX | AEROSOL, FOAM | TOPICAL | 10946101 | Oct. 1, 2030 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
EQ 1.5% BASE | ZILXI | JOURNEY | N213690 | May 28, 2020 | RX | AEROSOL, FOAM | TOPICAL | 8865139 | Oct. 1, 2030 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
EQ 1.5% BASE | ZILXI | JOURNEY | N213690 | May 28, 2020 | RX | AEROSOL, FOAM | TOPICAL | 8992896 | Oct. 1, 2030 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
EQ 1.5% BASE | ZILXI | JOURNEY | N213690 | May 28, 2020 | RX | AEROSOL, FOAM | TOPICAL | 9675700 | Oct. 1, 2030 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
EQ 100MG BASE/VIAL | MINOCIN | REMPEX | N050444 | None | RX | INJECTABLE | INJECTION | 9084802 | May 12, 2031 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 100MG BASE/VIAL | MINOCIN | REMPEX | N050444 | None | RX | INJECTABLE | INJECTION | 9278105 | May 12, 2031 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10398641 | Sept. 8, 2037 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
EQ 4% BASE | AMZEEQ | JOURNEY | N212379 | Oct. 18, 2019 | RX | AEROSOL, FOAM | TOPICAL | 10849847 | Sept. 8, 2037 | TREATMENT OF NON-NODULAR ACNE VULGARIS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tetracycline resistance protein, class B | Transporter | IC50 | 5.64 | WOMBAT-PK | |||||
30S ribosomal protein S4 | Ribosomal protein | Ka | 6 | WOMBAT-PK | |||||
30S ribosomal protein S9 | Ribosomal protein | Ka | 5.76 | WOMBAT-PK |
ID | Source |
---|---|
4019841 | VUID |
N0000147928 | NUI |
D00850 | KEGG_DRUG |
13614-98-7 | SECONDARY_CAS_RN |
4017916 | VANDF |
4019841 | VANDF |
C0026187 | UMLSCUI |
CHEBI:50694 | CHEBI |
MIY | PDB_CHEM_ID |
CHEMBL1434 | ChEMBL_ID |
CHEMBL1200881 | ChEMBL_ID |
D008911 | MESH_DESCRIPTOR_UI |
DB01017 | DRUGBANK_ID |
10831 | IUPHAR_LIGAND_ID |
1646 | INN_ID |
FYY3R43WGO | UNII |
54675783 | PUBCHEM_CID |
6979 | RXNORM |
1213 | MMSL |
21389 | MMSL |
5118 | MMSL |
d00110 | MMSL |
002754 | NDDF |
004864 | NDDF |
13512003 | SNOMEDCT_US |
372653009 | SNOMEDCT_US |
52886009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
minocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9935 | TABLET, FILM COATED, EXTENDED RELEASE | 65 mg | ORAL | NDA authorized generic | 29 sections |
minocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9935 | TABLET, FILM COATED, EXTENDED RELEASE | 65 mg | ORAL | NDA authorized generic | 29 sections |
minocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9936 | TABLET, FILM COATED, EXTENDED RELEASE | 115 mg | ORAL | NDA authorized generic | 29 sections |
minocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9936 | TABLET, FILM COATED, EXTENDED RELEASE | 115 mg | ORAL | NDA authorized generic | 29 sections |
Minocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-7805 | CAPSULE | 100 mg | ORAL | ANDA | 24 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3153 | CAPSULE | 75 mg | ORAL | ANDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5694 | CAPSULE | 50 mg | ORAL | ANDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5695 | CAPSULE | 100 mg | ORAL | ANDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5385 | TABLET, EXTENDED RELEASE | 45 mg | ORAL | ANDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5386 | TABLET, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5387 | TABLET, EXTENDED RELEASE | 135 mg | ORAL | ANDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6888 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
Ximino | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10631-330 | CAPSULE, EXTENDED RELEASE | 45 mg | ORAL | NDA | 26 sections |
Ximino | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10631-331 | CAPSULE, EXTENDED RELEASE | 90 mg | ORAL | NDA | 26 sections |
Ximino | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10631-332 | CAPSULE, EXTENDED RELEASE | 135 mg | ORAL | NDA | 26 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-482 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-482 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-482 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-482 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-483 | CAPSULE | 75 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-483 | CAPSULE | 75 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-483 | CAPSULE | 75 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-483 | CAPSULE | 75 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-484 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-484 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-484 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
Minocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-484 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
MINOCYCLINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-485 | TABLET | 50 mg | ORAL | ANDA | 14 sections |
MINOCYCLINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-485 | TABLET | 50 mg | ORAL | ANDA | 14 sections |
MINOCYCLINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-485 | TABLET | 50 mg | ORAL | ANDA | 14 sections |